Olutasidenib

Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is taken by mouth.

The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis. Olutasidenib was approved for medical use in the United States in December 2022, based on the phase 1 results of a phase 1/2 trial.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1338707943 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001338707943 · captured 2026-02-16 · ledger · version history

Cite this page as: encyclopegia.org, “Olutasidenib”, snapshot enwiki-001338707943. https://encyclopegia.org/a/olutasidenib

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.